Bortezomib
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
Administer by SUBCUTANEOUS (SC) injection into the thighs or abdomen (strongly preferred over intravenous injection due to dramatically lower incidence of peripheral neuropathy). Can also be administered by rapid 3 to 5 second intravenous bolus. Never administer intrathecally. Standard cycles administer on days 1, 4, 8, and 11 of a 21-day cycle, maintaining at least 72 hours between consecutive doses. MANDATORY: Antiviral prophylaxis (e.g. acyclovir 400 mg twice daily) is required to prevent herpes zoster reactivation.
⚠️ Side Effects
Common: Peripheral sensory neuropathy (numbness, neuropathic pain in feet/hands), fatigue, diarrhea, nausea, thrombocytopenia (cyclical nadir at day 11 with rapid recovery), constipation. Rare/Severe: Severe autonomic neuropathy, posterior reversible encephalopathy syndrome (PRES), congestive heart failure, acute lung injury, and herpes zoster reactivation.
🛡️ Safety Warnings
Subcutaneous administration is strongly recommended over IV to reduce severe peripheral neuropathy by up to 50%. Mandatory concomitant antiviral prophylaxis against shingles (Herpes zoster). Fatal if administered intrathecally. Substrate of CYP3A4.
Jan Aushadhi Products containing Bortezomib
Found 3 generic formulation(s) containing this active ingredient.
Bortezomib Injection 3.5 mg
Bortezomib Injection (2mg, 2.5mg, 3.5mg) is a dipeptidyl boronic acid reversible inhibitor of the 26S proteasome on the WHO Model List of Essential Medicines. It binds to the chymotrypsin-like catalytic site of the 20S core particle, preventing degradation of ubiquitinated proteins. This leads to toxic accumulation of intracellular polyubiquitinated proteins, stabilization of I-kappa-B-alpha, blockade of nuclear factor-kappa B (NF-kB) activation, and activation of the unfolded protein stress response, selectively killing multiple myeloma cells. Indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.
Bortezomib 2mg powder for Injection
Bortezomib Injection (2mg, 2.5mg, 3.5mg) is a dipeptidyl boronic acid reversible inhibitor of the 26S proteasome on the WHO Model List of Essential Medicines. It binds to the chymotrypsin-like catalytic site of the 20S core particle, preventing degradation of ubiquitinated proteins. This leads to toxic accumulation of intracellular polyubiquitinated proteins, stabilization of I-kappa-B-alpha, blockade of nuclear factor-kappa B (NF-kB) activation, and activation of the unfolded protein stress response, selectively killing multiple myeloma cells. Indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.
Bortezomib 2.5mg powder for Injection
Bortezomib Injection (2mg, 2.5mg, 3.5mg) is a dipeptidyl boronic acid reversible inhibitor of the 26S proteasome on the WHO Model List of Essential Medicines. It binds to the chymotrypsin-like catalytic site of the 20S core particle, preventing degradation of ubiquitinated proteins. This leads to toxic accumulation of intracellular polyubiquitinated proteins, stabilization of I-kappa-B-alpha, blockade of nuclear factor-kappa B (NF-kB) activation, and activation of the unfolded protein stress response, selectively killing multiple myeloma cells. Indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Bortezomib.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Bortezomib Injection 3.5 mg | Vial | ₹1020.94 | ZORTEMIB, JOHNSON & JOHNSON PRIVATE LIMITED | ₹29930.00 | 97% Save |
| Bortezomib 2mg powder for Injection | Vial with WFI | ₹665.63 | BORVIZ, BORTENAT, BORTRAC, BORTIVA, ZOBISTED | ₹3779.88 | 82% Save |
| Bortezomib 2.5mg powder for Injection | Vial with WFI | Under Process | N/A | N/A | N/A |
Frequently Asked Questions (FAQ)
Get answers to common queries about Bortezomib generics.